BACKGROUND The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal. METHODS We accessed Ethiopian Universities' online repository library, Google Scholar, PubMed, Web of Science, and Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by using Egger's regression test. The pooled prevalence was estimated using the DerSimonian-Laird random-effects model. We employed the sensitivity analysis to see the presence of outlier result in the included studies. RESULTS The overall human immunodeficiency treatment failure was 15.9% (95% confidence interval: 11.6-20.1%). Using immunological, virological, and clinical definition, human immunodeficiency treatment failure was 10.2% (95% confidence interval: 6.9-13.6%), 5.6% (95% confidence interval: 2.9-8.3%), and 6.3% (95% confidence interval: 4.6-8.0%), respectively. The pooled effects of World Health Organization clinical stage III/IV (Adjusted Odd Ratio = 1.9; 95% CI: 1.3-2.6), presence of opportunistic infections (Adjusted Odd Ratio = 1.8; 95% CI: 1.2-2.4), and poor adherence to highly active antiretroviral therapy (Adjusted Odd Ratio = 8.1; 95% CI: 4.3-11.8) on HIV treatment failure were estimated. CONCLUSIONS Human immunodeficiency virus treatment failure in Ethiopia found to be high. Being on advanced clinical stage, presence of opportunistic infections, and poor adherence to highly active antiretroviral therapy were the contributing factors of human immunodeficiency virus treatment failure. Human immunodeficiency virus intervention programs need to address the specified contributing factors of human immunodeficiency virus treatment failure. Behavioral intervention to prevent treatment interruption is required to sustain human immunodeficiency virus treatment adherence. PROTOCOL REGISTRATION It has been registered in the PROSPERO database with a registration number of CRD42018100254.

中文翻译：

---

埃塞俄比亚的艾滋病毒/艾滋病治疗失败及相关因素：荟萃分析。

背景 在埃塞俄比亚的背景下，人类免疫缺陷病毒治疗失败和相关因素的国家负担需要为实现新的雄心勃勃的未来目标提供证据。方法 我们访问了埃塞俄比亚大学的在线知识库图书馆、Google Scholar、PubMed、Web of Science 和 Scopus 以获取研究文章。我们运行 I 平方统计来查看异质性。通过使用 Egger 回归检验检查发表偏倚。使用 DerSimonian-Laird 随机效应模型估计汇总患病率。我们采用敏感性分析来查看纳入研究中异常值结果的存在。结果 总体人类免疫缺陷治疗失败率为 15.9%（95% 置信区间：11.6-20.1%）。使用免疫学、病毒学和临床定义，人类免疫缺陷治疗失败率分别为 10.2%（95% 置信区间：6.9-13.6%）、5.6%（95% 置信区间：2.9-8.3%）和 6.3%（95% 置信区间：4.6-8.0%）。世界卫生组织临床 III/IV 期（调整奇数比 = 1.9；95% CI：1.3-2.6）、机会性感染（调整奇数比 = 1.8；95% CI：1.2-2.4）和差的综合影响估计对 HIV 治疗失败的高活性抗逆转录病毒治疗的依从性（调整奇数比 = 8.1；95% CI：4.3-11.8）。结论 在埃塞俄比亚发现人类免疫缺陷病毒治疗失败率很高。处于晚期临床阶段、机会性感染的存在以及对高效抗逆转录病毒治疗的依从性差是导致人类免疫缺陷病毒治疗失败的因素。人类免疫缺陷病毒干预计划需要解决导致人类免疫缺陷病毒治疗失败的特定因素。需要进行行为干预以防止治疗中断，以维持人类免疫缺陷病毒治疗的依从性。PROTOCOL REGISTRATION 已在 PROSPERO 数据库中注册，注册号为 CRD42018100254。